Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Reeder

Showing results (421-430 of 465) with videos related to

Pageof 47
Sort By:
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Magnetic Resonance in Medicine|April 16, 2016
Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantomDiego Hernando, Samir D Sharma, Mounes Aliyari Ghasabeh, et al.
British Journal of Haematology|November 24, 2011
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myelomaMeaghan L Khan, Craig B Reeder, Shaji K Kumar, et al.
American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.
Mayo Clinic Proceedings|March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statementAngela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology|January 2, 2023
Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experienceKaran L Chohan, Jonas Paludo, Nishanth Vallumsetla, et al.
Leukemia & Lymphoma|January 12, 2018
A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphomaMohamad Bassam Sonbol, Talal Hilal, Amylou C Dueck, et al.
Magnetic Resonance in Medicine|February 10, 2021
Temperature-corrected proton density fat fraction estimation using chemical shift-encoded MRI in phantomsRuvini Navaratna, Ruiyang Zhao, Timothy J Colgan, et al.
Haematologica|December 4, 2025
Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemiaKaran Chohan, Jonas Paludo, Surendra Dasari, et al.
Radiology|January 19, 2021
Linearity and Bias of Proton Density Fat Fraction as a Quantitative Imaging Biomarker: A Multicenter, Multiplatform, Multivendor Phantom StudyHouchun H Hu, Takeshi Yokoo, Mustafa R Bashir, et al.
Pageof 47

Showing results (421-430 of 465) with videos related to

Sort By:
Pageof 47
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Magnetic Resonance in Medicine|April 16, 2016
Multisite, multivendor validation of the accuracy and reproducibility of proton-density fat-fraction quantification at 1.5T and 3T using a fat-water phantomDiego Hernando, Samir D Sharma, Mounes Aliyari Ghasabeh, et al.
British Journal of Haematology|November 24, 2011
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myelomaMeaghan L Khan, Craig B Reeder, Shaji K Kumar, et al.
American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.
Mayo Clinic Proceedings|March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statementAngela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology|January 2, 2023
Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experienceKaran L Chohan, Jonas Paludo, Nishanth Vallumsetla, et al.
Leukemia & Lymphoma|January 12, 2018
A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphomaMohamad Bassam Sonbol, Talal Hilal, Amylou C Dueck, et al.
Magnetic Resonance in Medicine|February 10, 2021
Temperature-corrected proton density fat fraction estimation using chemical shift-encoded MRI in phantomsRuvini Navaratna, Ruiyang Zhao, Timothy J Colgan, et al.
Haematologica|December 4, 2025
Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemiaKaran Chohan, Jonas Paludo, Surendra Dasari, et al.
Radiology|January 19, 2021
Linearity and Bias of Proton Density Fat Fraction as a Quantitative Imaging Biomarker: A Multicenter, Multiplatform, Multivendor Phantom StudyHouchun H Hu, Takeshi Yokoo, Mustafa R Bashir, et al.
Pageof 47